Skip to Content
Merck
CN

N3785

Sigma-Aldrich

Nabilone

solid, ≥98% (HPLC)

Synonym(s):

LY-109514

Sign Into View Organizational & Contract Pricing

About This Item

Empirical Formula (Hill Notation):
C24H36O3
CAS Number:
51022-71-0
Molecular Weight:
372.54
MDL number:
MFCD00941490
UNSPSC Code:
12352200
PubChem Substance ID:
329818640
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

Assay

≥98% (HPLC)

form

solid

drug control

USDEA Schedule II; stupéfiant (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

color

white

solubility

DMSO: soluble ~18 mg/mL
H2O: insoluble

application(s)

forensics and toxicology
veterinary

shipped in

wet ice

storage temp.

2-8°C

SMILES string

CCCCCCC(C)(C)c1cc(O)c2[C@@H]3CC(=O)CC[C@H]3C(C)(C)Oc2c1

InChI

1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1

InChI key

GECBBEABIDMGGL-RTBURBONSA-N

Related Categories

Biochem/physiol Actions

CB1 and CB2 cannabinoid receptor agonist.

Features and Benefits

This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Warning

Hazard Statements

H302,H336,H361

Hazard Classifications

Acute Tox. 4 Oral - Repr. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000082248
071M4604V
087K4623
063K4619

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jarkko Kalliomäki et al.
Clinical and experimental pharmacology & physiology, 39(4), 336-342 (2012-01-12)
The aim of the present study was to investigate the effects of nabilone on capsaicin-induced pain and hyperalgesia, as well as on biomarkers of cannabinoid central nervous system (CNS) effects. A randomized, double-blind, placebo-controlled, crossover study was conducted in 30
Roger G Pertwee
British journal of pharmacology, 156(3), 397-411 (2009-02-20)
Medicines that activate cannabinoid CB(1) and CB(2) receptor are already in the clinic. These are Cesamet (nabilone), Marinol (dronabinol; Delta(9)-tetrahydrocannabinol) and Sativex (Delta(9)-tetrahydrocannabinol with cannabidiol). The first two of these medicines can be prescribed to reduce chemotherapy-induced nausea and vomiting.
Sepideh Pooyania et al.
Archives of physical medicine and rehabilitation, 91(5), 703-707 (2010-05-04)
To determine whether nabilone, a synthetic cannabinoid, alleviates spasticity in people with spinal cord injury (SCI). A double-blind, placebo-controlled crossover study. Outpatient rehabilitation clinics. We recruited volunteers (N=12) with SCI and spasticity. One subject, a paraplegic man, dropped out of
Joshua A Lile et al.
Clinical neuropharmacology, 33(5), 235-242 (2010-09-15)
The central effects of Δ-tetrahydrocannabinol (Δ-THC), the primary active constituent of cannabis, are attributed to cannabinoid CB1 receptor activity, although clinical evidence is limited. Drug discrimination has proven useful for examining the neuropharmacology of drugs, as data are concordant with
Joshua A Lile et al.
Drug and alcohol dependence, 116(1-3), 86-92 (2011-01-14)
Agonist replacement treatment is a promising strategy to manage cannabis-use disorders. The aim of this study was to assess the combined effects of the synthetic cannabinoid agonist nabilone and Δ⁹-tetrahydrocannabinol (Δ⁹-THC) using drug-discrimination procedures, which are sensitive to drug interactions.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service